Literature DB >> 28439106

Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.

S Knop1, C Langer2, M Engelhardt3, L-O Mügge4, A Reichle5, W Rösler6, F Bassermann7, B Hertenstein8, A Kunitz9, C Röllig10, H Ostermann11, K Schäfer-Eckart12, M Ringhoffer13, A Günther14, C Junghanss15, H Biersack16, M Schreder1, A Liebert17, S Held17, H Einsele1, R C Bargou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28439106     DOI： 10.1038/leu.2017.124

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

Authors:  Frederic Garban; Michel Attal; Mauricette Michallet; Cyrille Hulin; Jean H Bourhis; Ibrahim Yakoub-Agha; Thierry Lamy; Gerald Marit; Frederic Maloisel; Christian Berthou; Mamoun Dib; Denis Caillot; Bernard Deprijck; Nicolas Ketterer; Jean-Luc Harousseau; Jean-Jacques Sotto; Philippe Moreau
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

2.  IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).

Authors:  J Krönke; F Kuchenbauer; M Kull; V Teleanu; L Bullinger; D Bunjes; A Greiner; S Kolmus; S Köpff; M Schreder; L-O Mügge; C Straka; M Engelhardt; H Döhner; H Einsele; F Bassermann; R Bargou; S Knop; C Langer
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

3.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

Authors:  Amrita Krishnan; Marcelo C Pasquini; Brent Logan; Edward A Stadtmauer; David H Vesole; Edwin Alyea; Joseph H Antin; Raymond Comenzo; Stacey Goodman; Parameswaran Hari; Ginna Laport; Muzaffar H Qazilbash; Scott Rowley; Firoozeh Sahebi; George Somlo; Dan T Vogl; Daniel Weisdorf; Marian Ewell; Juan Wu; Nancy L Geller; Mary M Horowitz; Sergio Giralt; David G Maloney
Journal:  Lancet Oncol       Date:  2011-09-29       Impact factor: 41.316

4.  Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

Authors:  Stefan Knop; Christian Gerecke; Peter Liebisch; Max S Topp; Uwe Platzbecker; Orhan Sezer; Christina Vollmuth; Karina Falk; Axel Glasmacher; Uwe Maeder; Hermann Einsele; Ralf C Bargou
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

5.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

6.  Graft-versus-myeloma effect: proof of principle.

Authors:  G Tricot; D H Vesole; S Jagannath; J Hilton; N Munshi; B Barlogie
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

7.  A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.

Authors:  Laura Rosiñol; José Antonio Pérez-Simón; Anna Sureda; Javier de la Rubia; Felipe de Arriba; Juan José Lahuerta; José David González; Joaquín Díaz-Mediavilla; Belén Hernández; Javier García-Frade; Dolores Carrera; Angel León; Miguel Hernández; Pascual Fernández Abellán; Juan Miguel Bergua; Jesús San Miguel; Joan Bladé
Journal:  Blood       Date:  2008-07-08       Impact factor: 22.113

8.  A comparison of allografting with autografting for newly diagnosed myeloma.

Authors:  Benedetto Bruno; Marcello Rotta; Francesca Patriarca; Nicola Mordini; Bernardino Allione; Fabrizio Carnevale-Schianca; Luisa Giaccone; Roberto Sorasio; Paola Omedè; Ileana Baldi; Sara Bringhen; Massimo Massaia; Massimo Aglietta; Alessandro Levis; Andrea Gallamini; Renato Fanin; Antonio Palumbo; Rainer Storb; Giovannino Ciccone; Mario Boccadoro
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

9.  Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Authors:  Ruth Eichner; Michael Heider; Vanesa Fernández-Sáiz; Frauke van Bebber; Anne-Kathrin Garz; Simone Lemeer; Martina Rudelius; Bianca-Sabrina Targosz; Laura Jacobs; Anna-Maria Knorn; Jolanta Slawska; Uwe Platzbecker; Ulrich Germing; Christian Langer; Stefan Knop; Herrmann Einsele; Christian Peschel; Christian Haass; Ulrich Keller; Bettina Schmid; Katharina S Götze; Bernhard Kuster; Florian Bassermann
Journal:  Nat Med       Date:  2016-06-13       Impact factor: 53.440

10.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728
View more
  3 in total

1.  Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance.

Authors:  Sophia Danhof; Martin Schreder; Stefan Knop; Leo Rasche; Susanne Strifler; Claudia Löffler; Tea Gogishvili; Hermann Einsele; Michael Hudecek
Journal:  Haematologica       Date:  2017-11-30       Impact factor: 9.941

2.  Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.

Authors:  Rajshekhar Chakraborty; Irbaz Bin Riaz; Saad Ullah Malik; Naimisha Marneni; Alex Mejia Garcia; Faiz Anwer; Alok A Khorana; S Vincent Rajkumar; Shaji Kumar; M Hassan Murad; Zhen Wang; Safi U Khan; Navneet S Majhail
Journal:  Cancer       Date:  2020-01-08       Impact factor: 6.860

3.  Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis.

Authors:  Wenjing Wang; Shubin Niu; Luxin Qiao; Feili Wei; Jiming Yin; Shanshan Wang; Yabo Ouyang; Dexi Chen
Journal:  Biomed Res Int       Date:  2019-02-11       Impact factor: 3.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.